Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Key Highlights
- ➤ZP9830 multiple doses were safe and well tolerated in 32 healthy participants
- ➤No serious or severe adverse events or dose-limiting safety findings observed
- ➤Phase 1b plaque psoriasis trial has already started with efficacy endpoints
- ➤Phase 2 trial in an additional autoimmune disease planned for H1 2027
Expert Statements
David Kendall, Chief Medical Officer of Zealand Pharma
“These results represent an encouraging milestone for ZP9830. In this multiple ascending dose part of the Phase 1 trial, ZP9830 was well tolerated and no dose limiting safety findings were observed. The findings support continued development in studies of longer duration”
David Kendall, Chief Medical Officer of Zealand Pharma
“This brings us one step closer to our goal of delivering a novel immunological treatment to patients. We are excited to investigate the potential of this novel asset across multiple autoimmune and inflammatory diseases. Our Phase 1b trial in plaque psoriasis is already under way, and the data announced today give us the confidence to expand the development program and explore an additional autoimmune disease in 2027.”
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 * ZP9830 is a novel Kv1.3 ion channel blocker with pipeline-in-a-product opportunity across a broad range of cell-mediated autoimmune diseases * Multiple doses of ZP9830 were well tolerated with no serious or severe adverse events or dose-limiting safety findings * Development program is progressing rapidly with a Phase 1b trial in people with plaque psoriasis recently initiated, and a Phase 2 trial in an additional autoimmune disease planned for initiation in H1 2027 Copenhagen, Denmark, October 19, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive Phase 1 multiple ascending dose (MAD) topline results for the company’s novel Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-center, randomized, double-blind, placebo-controlled Phase 1 trial was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple doses of ZP9830 in 32 healthy male and female participants.
Get started
Create a free account to read the full story.